Skip to main content

Multi-potent adult progenitor cells to treat stroke

Cel

Successful therapy for stroke will be achieved using cells that can limit ischemic injury and differentiate into the multiple cell types needed for restoring blood flow and neural circuits, and would be available for therapy 'off the shelf'. As Multipotent Adult Progenitor Cells (MAPCs) differentiate into vascular and neural cells, and reconstitute damaged tissues in vivo, we hypothesize that MAPCs is an ideal allogeneic cell product to treat stroke.
In WP1, WP2 and WP3, we will develop approaches to generate committed vascular cells and neuroprogenitors, and identify key molecular events that guide differentiation. WPs 4-7 will rigorously evaluate the pre-clinical efficacy of allogeneic MAPCs or their progeny in stroke. This will include development of noninvasive imaging techniques to follow the fate of grafted cells and evaluate their impact on CNS function (WP4).
We will compare the efficacy of MAPCs with that of till now 'gold-standard' stem cell populations in stroke, and determine mechanisms underlying observed effects (WP5).
We will examine the immunogenicity of MAPCs and their differentiated progeny in vitro (WP6) and in vivo using mice with a 'human immune system' (WP7).
Studies in WP9 will develop clinical grade culture systems to generate human MAPCs and, if needed, lineage committed progeny. Studies in WP8 will develop a framework in which to develop clinical grade stem cell products in an ethically responsible manner. Specific attention to the management of the project.
The management, exploitation and dissemination of the project will be ensured through WP10. These studies will lay the foundation for clinical trials of MAPCs in stroke in Europe in subsequent years. The highly innovative methods, tools and technologies that will be developed will not only be applicable in the area of stem cell based therapies for stroke, but may significantly advance use of human stem cells in regenerative medicine.'

Zaproszenie do składania wniosków

FP6-2005-LIFESCIHEALTH-6
Zobacz inne projekty w ramach tego zaproszenia

Koordynator

KATHOLIEKE UNIVERSITEIT LEUVEN
Adres
Oude Markt 13
Leuven
Belgia

Zobacz na mapie

Uczestnicy (7)

VLAAMS INTERUNIVERSITAIR INSTITUUT VOOR BIOTECHNOLOGIE VZW
Belgia
Adres
Rijvisschestraat 120
Zwijnaarde

Zobacz na mapie

UNIVERSITY OF NAVARRA
Hiszpania
Adres
Campus Universitario S/n Edificio Central
Pamplona

Zobacz na mapie

INSTITUTE FOR RESEARCH IN BIOMEDICINE
Szwajcaria
Adres
Via V. Vela 6
Bellinzona

Zobacz na mapie

KAROLINSKA INSTITUTET
Szwecja
Adres
Nobels Väg 5
Stockholm

Zobacz na mapie

REGENESYS
Belgia
Adres
Avenue Louise 331-333
Brussels

Zobacz na mapie

GUERBET
Francja
Adres
15, Rue Des Vanesses
Villepinte

Zobacz na mapie

UNIVERSITAT DE VALÈNCIA. ESTUDI GENERAL
Hiszpania
Adres
Avda Blasco Ibañez 13
22085 Valencia

Zobacz na mapie